NSIS B logo

Novozymes A/S Stock Price

CPSE:NSIS B Community·DKK 189.7b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 34 Fair Values set on narratives written by author

NSIS B Share Price Performance

DKK 407.20
-46.90 (-10.33%)
DKK 471.06
Fair Value
DKK 407.20
-46.90 (-10.33%)
13.6% undervalued intrinsic discount
DKK 471.06
Fair Value
Price DKK 407.20
AnalystConsensusTarget DKK 471.06
AnalystHighTarget DKK 548.58
AnalystLowTarget DKK 380.00

NSIS B Community Narratives

·
Fair Value DKK 471.06 13.6% undervalued intrinsic discount

Enzyme Biosolutions And Preventive Health Trends Will Drive Long-Term Expansion

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
·
Fair Value DKK 548.58 25.8% undervalued intrinsic discount

Emerging Markets And Biofuels Will Support A Stronger Long Term Outlook

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value DKK 380 7.2% overvalued intrinsic discount

Bioenergy And Biosolutions Demand Will Support Earnings Despite Regulatory And Competitive Headwinds

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
DKK 548.58
25.8% undervalued intrinsic discount
Revenue
9.59% p.a.
Profit Margin
20.97%
Future PE
34x
Price in 2029
DKK 646.85
DKK 380
7.2% overvalued intrinsic discount
Revenue
6.12% p.a.
Profit Margin
19.32%
Future PE
35.9x
Price in 2028
DKK 447.87
DKK 471.06
13.6% undervalued intrinsic discount
Revenue
6.83% p.a.
Profit Margin
18.91%
Future PE
44.56x
Price in 2028
DKK 555.11

Trending Discussion

Updated Narratives

NSIS B logo

NSIS B: Consumer Ingredients And Probiotics Expansion Will Support Premium Multiple

Fair Value: DKK 548.58 25.8% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
NSIS B logo

Bioenergy And Biosolutions Demand Will Support Earnings Despite Regulatory And Competitive Headwinds

Fair Value: DKK 380 7.2% overvalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
NSIS B logo

Enzyme Biosolutions And Preventive Health Trends Will Drive Long-Term Expansion

Fair Value: DKK 471.06 13.6% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Solid track record with excellent balance sheet and pays a dividend.

1 Risk
3 Rewards

Novozymes A/S Key Details

€4.2b

Revenue

€1.9b

Cost of Revenue

€2.3b

Gross Profit

€1.7b

Other Expenses

€596.7m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 20, 2026
1.28
55.86%
14.21%
27.6%
View Full Analysis

About NSIS B

Founded
n/a
Employees
11098
CEO
Ester Baiget
WebsiteView website
www.novonesis.com

Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition. The company also offers bioenergy solutions including biodiesel; biogas from agricultural and industrial residues and food waste; biomass; carbon capture; ethanol for liquefaction, saccharification, fermentation, and fiber conversion; and renewable diesel. In addition, it provides dishwashing, home cleaning, laundry, medical, and industrial and institutional cleaning services; gastrointestinal, immune, mental, women’s, children’s cardiometabolic, and oral human health solutions. Further, the company offers corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; silage, diary and beef cattle, poultry, swine, aquaculture solutions; pet care solutions; leather and textiles solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions; and distilling, oils and fats, sustainable plastic solutions. Additionally, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novozymes A/S is headquartered in Lyngby, Denmark.

Recent NSIS B News & Updates

Narrative Update Jun 26

NSIS B: Consumer Ingredients And Probiotics Expansion Will Support Premium Multiple

Analysts have nudged the fair value estimate for Novozymes (Novonesis) slightly lower to DKK 548.58 from about DKK 560, reflecting a blend of trimmed Street price targets around DKK 552 and DKK 460, as well as updated assumptions for revenue growth, profit margins and a more conservative future P/E of 34x. Analyst Commentary Recent Street research on Novozymes reflects a mix of fine tuning on price targets and ratings, with bullish analysts focusing on the company’s positioning in consumer ingredients and its ability to support premium valuation metrics.
Analysis Article Jun 22

Novozymes (CPSE:NSIS B) Stock Could Be 31% Below Fair Value After UndoAge Deal

UndoAge partnership puts Novozymes (CPSE:NSIS B) in focus The new Memorandum of Understanding between UndoAge and Novonesis to co develop probiotics and postbiotics for the Chinese consumer health market puts fresh attention on Novozymes stock for investors tracking microbiome related opportunities. See our latest analysis for Novozymes. At a share price of DKK394.2, Novozymes has seen momentum build recently, with a 30 day share price return of 5.40% and a 90 day gain of 12.44%, even as the...

Recent updates

No updates

Novozymes A/S Competitors